Stack
Is the peptide identity interpretable at sequence or structure-string level?
Are molecular graph, topology, or 3D coordinates available?
Can basic developability descriptors be computed?
Is this peptide linked to approved or named product context?
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
How stable is the peptide in biological matrices or protease systems?
What evidence describes clearance or persistence?
What safety, toxicity, or tolerability evidence is attached?
Can every measurement be reviewed in one cross-domain table?
Can the peptide identity be checked against reported names, sequence notation, and reference links?
Can this profile view be reproduced from structured records?
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
How stable is the peptide in biological matrices or protease systems?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Features are shown only when a reported notation or topology record supports them.
Cysteine linkage reported between positions 1 and 6.
| Experimental structure match |
| experimental |
| 9 aa |
| Open | Experimental structure match | experimental | 9 aa |
Grouped composition is often more interpretable than a long amino-acid list.
The projection assumes an α-helix conformation; a long μH arrow indicates an amphipathic helix, common in antimicrobial peptides.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | ~= 40 min ~= 2400 seconds | Comparable | Manual extraction from PubMed-indexed clinical PK abstract; plasma oxytocin sampling during labor-augmentation infusion · human · plasma | Route: intravenous infusion · Dose/window: labor augmentation infusion; 1 mU/min initial dose; 1 mU/min increments every 4... · Time: approximately 40 min after each dose step | Open |
The same three research-facing layers are used across ADMETatlas.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 30 % | Comparable | PepTherDia curated product PK field · plasma protein | Route: IV, IM · 2 · Oxytocin · exact product name match · exact or normalized match | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 0.00815 mL/g | Comparable | Intracarotid injection · blood-brain barrier | VD | Open |
| 2 | 0.018 %/g | Comparable | Intravenous injection · blood-brain barrier | % injected dose | Open |
| 3 | 1.09 μL/g/min | Comparable | Intravenous injection · blood-brain barrier | PS | Open |
| 4 | Observation raw_value: 0.00815 ml/g; result: 0.00815 ml/g; transport_type: Permeability | Reported | NA · NA · NA · blood-brain barrier | Route: Intracarotid injection · Permeability | Open |
| 5 | Observation raw_value: 0.018 %/g; result: 0.018 %/g; transport_type: Permeability | Reported | NA · NA · NA · blood-brain barrier | Route: Intravenous · Permeability | Open |
| 6 | Observation raw_value: 1.09 μL/(g x min); result: 1.09 μL/(g x min); transport_type: Permeability | Reported | NA · NA · NA · blood-brain barrier | Route: Intravenous · Permeability | Open |
| 7 | Observation transport_type: Permeability | Reported | NA · NA · NA · blood-brain barrier | Route: Peripheral administration · Permeability | Open |
cell monolayer
barrier evidence
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 1 days 86400 seconds | Comparable | HPLC and LC/ITMS · Bacterial strain B-9 cell culture | Dose/window: 1mg/mL · Time: Room Temperature · Hydolytic activity of bacterial strain B-9 · in vitro | Open |
| 2 | 6.78 minutes 406.8 seconds | Comparable | Radioimmunoassay · Intravenous injection of oxytocin in normal mares | Dose/window: 180mg · Time: 60 minutes · Blood protease · in vivo | Open |
| 3 | 6.78 minutes 406.8 seconds | Comparable | Radioimmunoassay · Intravenous injection of oxytocin in normal mares | Dose/window: 90mg · Time: 60 minutes · Blood protease · in vivo | Open |
The identity reference does not expose a sequence string.
CYIQNCPLG
CYIQNCPLG
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.